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Abstract: Traumatic brain injury (TBI) is one of the leading causes of mortality and disability world-
wide without any validated biomarker or set of biomarkers to help the diagnosis and evaluation of
the evolution/prognosis of TBI patients. To achieve this aim, a deeper knowledge of the biochemical
and pathophysiological processes triggered after the trauma is essential. Here, we identified the
serum amyloid A1 protein-Toll-like receptor 4 (SAA1-TLR4) axis as an important link between in-
flammation and the outcome of TBI patients. Using serum and mRNA from white blood cells (WBC)
of TBI patients, we found a positive correlation between serum SAA1 levels and injury severity, as
well as with the 6-month outcome of TBI patients. SAA1 levels also correlate with the presence of
TLR4 mRNA in WBC. In vitro, we found that SAA1 contributes to inflammation via TLR4 activation
that releases inflammatory cytokines, which in turn increases SAA1 levels, establishing a positive
proinflammatory loop. In vivo, post-TBI treatment with the TLR4-antagonist TAK242 reduces SAA1
levels, improves neurobehavioral outcome, and prevents blood–brain barrier disruption. Our data
support further evaluation of (i) post-TBI treatment in the presence of TLR4 inhibition for limiting
TBI-induced damage and (ii) SAA1-TLR4 as a biomarker of injury progression in TBI patients.
Keywords: traumatic brain injury; neuroinflammation; prognosis; biomarkers; immunomodulation
1. Introduction
Traumatic brain injury (TBI) is one of the leading causes of mortality and disability
worldwide, and it is usually initiated after a blunt impact, penetration through the skull
into the brain, or exposure to explosive blast. TBI has been classified from different points
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of view including the classic severity score according to the degree of alteration of the
consciousness level (mild, moderate, or severe), or according to the type of injury identified
in the computed tomography (focal or diffuse) [1,2]. TBI has a complex pathophysiology
that produces mechanical injury within seconds to neurons, glia, and blood vessels. This
primary damage triggers a secondary process from different etiologies, i.e., ischemia,
excitotoxicity, edema, or inflammation, that evolves from weeks to months [3,4]. In animals,
inflammation is increasingly recognized to be an important cause of secondary brain
injury, and it is initiated by the release of damage associated molecular patterns (DAMPs)
from necrotic cells leading to the activation of astrocytes and microglia [5]. Release of
proinflammatory cytokines and chemokines lead to further breakdown of the Blood–Brain
Barrier (BBB) and recruitment of peripheral inflammatory cells [6].
Toll-like receptors (TLRs) are a class of transmembrane pattern-recognition recep-
tor family that play a key role in the activation of innate immune system in response to
pathogens (infection), or to resolve damage produced by DAMPs (sterile response) [3–7].
TLR4 is highly expressed in macrophage/microglia and its activation by different DAMPs
(i.e., HMGB1 or Hsp90) initiates an inflammatory cascade in several acute CNS-pathologies
and after brain injuries [8]. It has been recently shown that the absence of TLR4 protects
against TBI by affecting the polarization of microglia, and therefore decreasing the inflam-
matory response [9]. Moreover, TLR4 inhibition by resatorvid (TAK242) decreases the
development of the secondary injury after TBI in a mouse model [10]. Although all the
aforementioned strongly support that TLR4 has a crucial role for the pathophysiology of
TBI, its contribution to the inflammatory process to secondary TBI in the clinical scenery is
less well established.
A biomarker is a surrogate and objective indicator of biological processes occurring
in an individual that provides information about the pathology of a disease/condition
or the response to a pathogen or to a treatment [11]. In the context of TBI, biomarkers
have the potential to be used as diagnostic markers of injury severity, response to treat-
ment (monitoring biomarkers), or even as predictors of outcomes (predictive biomarkers).
Noninvasive and feasible techniques such as the use of plasma biomarkers are a prior-
ity in current medicine [11–13]. Discovering biomarkers that help us make decisions in
clinical practice in a patient who has recently suffered a TBI is essential to determine the
biochemical and pathophysiological processes that are triggered after the trauma [13]. The
Serum Amyloid A1 (SAA1) protein is one of the acute-phase response proteins, mainly
synthetized in the liver, which is released into the systemic circulation in response to inflam-
mation [14]. Recently, we have found that the SAA1 protein is a potential intracranial and
extracranial clinical severity biomarker in TBI [15]. The aim of this study was to evaluate
the individual and combined outcome prediction ability of SAA1 and TLR4, both related
with inflammation and to compare them to S100β, a multifunctional protein that is found
in astrocytes, used as biomarker TBI [12–14]. Moreover, as SAA1 may serve as a DAMP, we
hypothesized that SAA1 may be an important link between inflammation and the outcome
of TBI patients. To validate this hypothesis, we examined the relation of SAA1 and TLR4,
both in samples of TBI patients and in the in vivo model of closed head injury (CHI) in
mice, as well as in in vitro cultures of glial cells.
2. Materials and Methods
2.1. Study Approval
All animal procedures and protocols (PROEX 109/18) were conducted in compliance
with the Guide for the Care and Use of Laboratory Animals and approved by the Ethics
Committee of Universidad Autónoma de Madrid (Madrid, Spain) and followed the AR-
RIVE Guidelines. The clinical study protocol was conducted in accordance with the ethical
standards of the institutional review board approved by the Ethics Committee of Hospital
Universitario La Paz (PI-2153). At admission, informed consent was obtained from all
patients (or their relatives in those patients presenting decreased level of consciousness).
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2.2. Human Samples
This observational prospective cohort study was conducted at the Department of
Neurosurgery of Hospital Universitario La Paz between April 2017 and October 2018.
Patients were included in accordance with the following criteria: age between 18 and
85 years, admitted to our hospital with the diagnosis of closed head injury, presenting
within 24 h of injury, and admitted to the Intensive Care Unit or Neurosurgery Ward.
Exclusion criteria were as follows: presence of previous neurological disease or cognitive
impairment or inability to perform head CT, to collect biological sample, or to complete
a proper follow-up. Venous blood samples were obtained at 24 h, 72 h, and 7 days after
suffering TBI. Blood was allowed to clot, and after centrifugation (1000× g, 30 min) serum
was stored at −80 ◦C until analysis. A group of healthy controls, without clinical history of
TBI or major disease, were randomly collected with the objective of detecting those proteins
present in patients with TBI and comparing biomarker levels with the study cohort.
2.3. Intracranial Clinical Severity Evaluation
The impairment of consciousness levels was assessed by the GCS at hospital admission.
Mild injury was defined as a GCS score of 14 to 15. Moderate injury was defined as a
GCS of 9 to 13, and severe injury was defined as a GCS score of 3 to 8 (regardless of CT
scan findings).
2.4. Outcome
Outcomes were evaluated in person or by mail or telephone with the patient or a close
relative using a validated questionnaire for assessment. Outcomes were ascertained using
the 6 months Glasgow Outcome Scale extended (GOSE). For statistical analysis, GOSE was
dichotomized into favorable (8/7/6) versus unfavorable (5/4/3/2/1) outcome.
2.5. ELISA Assay
Human blood was used to determine the levels of SAA1 with a specific ELISA (Cat.
No. EL10015, Anogen, ON, Canada) and the levels of S100B by CLIA (Cat. No. LIAISON
S100B 314701, Diasorin, Italy). Blood from mice was collected in EDTA-treated tubes and
centrifuged at 2500 rpm for 10 min to obtain serum. Cortex from contralateral and ipsilateral
hemispheres of mice brains were lysed in RIPA lysis buffer (0.5% Nonidet P-40, 0.1% sodium
dodecyl sulfate, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) and 100 µg
of protein was used to determine SAA1 levels. Cell culture supernatants from mixed glial
cultures were frozen until protein quantification. IL-1β, TNF-α, and SAA1 levels from
brains and glial cultures were measured by specific ELISA kits (Cat. No. DY401 for IL-1β,
DY410 for TNF-α, DY2948 for SAA1; R&D Systems, Minneapolis, MN, USA) according to
manufacturer’s protocols.
2.6. Animals
Three-month male C57BL/6J mice (25–30 g were used to perform the experiments.
Animals were group-housed under controlled temperature and lighting conditions and
ingested water and food ad libitum. Every effort was made to reduce the number of
animals used and their suffering.
2.7. Mixed Glial Cultures
Mixed glial cultures were prepared from cerebral cortices of 4-day-old C57BL/6J
mice as previously described [16]. Briefly, meninges and blood vessels were removed,
and forebrains were dissociated by repeated pipetting in DMEM/F12 medium (Fisher
Scientific, Madrid, Spain). Cells were seeded in DMEM/F12 with 20% FBS at a density of
3 × 105 cells/mL and maintained at 37 ◦C in humidified 5% CO2/95% air. Confluence was
reached at 10–12 days in vitro and cultures were treated with SAA1 recombinant protein
(R&D Systems, Minneapolis, MN, USA), TNF-α recombinant protein (R&D Systems, USA),
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IL-1β recombinant protein (R&D Systems, USA), LPS (Sigma-Aldrich, Madrid, Spain), and
TAK242 (Sigma-Aldrich, Madrid, Spain) in DMEM/F12 with 10% FBS.
2.8. Closed Head Injury (CHI) Model
CHI is a weight drop model in which the skull is exposed to a free-falling weight.
Procedures were adapted from Flierl et al. [17]. The injury was produced to the right
hemisphere between sagittal and lambdoid sutures by a weight dropped from 34 cm and
weighing 50 g in order to produce severe TBI (assessed 1 h after trauma by Neurological
Severity Score, described below). The head of the animals was placed on a hard surface
to reduce the dissipation of energy and generate a focal injury. Two hours before CHI,
animals were treated with buprenorphine 0.05 mg/kg subcutaneously for analgesia. Mice
were anesthetized with inhaled isoflurane before the impact and subjected to oxygen
administration after trauma until regular breath was restored.
Mice were divided in 3 groups: sham, not subjected to CHI; vehicle, treated with 0.9%
NaCl containing 3% DMSO; TAK242, treated with the TLR4 inhibitor TAK242 at 3 mg/kg
diluted in 0.9% NaCl containing 3% DMSO.
2.9. Neurological Severity Score (NSS) Test
The assessment of the severity of the injury, which correlates with the weight falling
height, is based on the evaluation of motor and neurobehavioral functions at 1 h after
trauma using the Neurological Severity Score (NSS), modified from Flierl et al. [17]. The
score consists of the evaluation of behavioral and neurological parameters, in which
10 points means a total neurological impairment. Mice with a score of 9 and 10 points were
sacrificed to avoid suffering according to the Guide for the Care and Use of Laboratory
Animals. Animals were treated intraperitoneally (i.p.) after the 1 h neurological test. NSS
were performed again at 24 h to determine possible differences between groups.
2.10. Blood–Brain Barrier Integrity Assessment
Evans Blue tracer (Sigma-Aldrich, Madrid, Spain) diluted at 2% in saline was injected
i.p. immediately after CHI for 1 h post-TBI analysis, following the 1-h NSS test for 24 h
post-TBI analysis, or 6 days post-TBI for 7 days post-TBI analysis. Animals were sacrificed
1 h, 24 h or 7 days after trauma and brains were extracted and sectioned in four 2 mm
slices using a mouse brain slicer. The slices were scanned, and total area of Evans Blue
extravasation was measured in each slice using the program ImageJ 1.52e (ImageJ software,
National Institutes of Health, Stapleton, NY, USA).
2.11. RNA Extraction and Quantitative Real-Time PCR
Total RNA from blood cells of controls and trauma patients were obtained using the
QIAamp® RNA Blood Mini Kit (Cat No. 52304, Qiagen, Germany). cDNA was synthetized
with the iScript cDNA synthesis kit (Cat No. 1708891, Biorad, Hercules, CA, USA) and real-
time PCR was performed on a QuantStudio 5 PCR system (Applied Biosystems, Foster City,
CA, USA). Expression of human TLR4 was analyzed using Taqman® gene expression assays
(FAM probe, Hs00152939_m1). mRNA expression was normalized against eukaryotic 18S
rRNA (VIC probe, 4310893E) in the same samples and calculated by the ∆/∆ Ct method.
2.12. Immunoblotting and Image Analysis
Mouse brain cortex and glial cultures were lysed in RIPA lysis buffer (0.5% Non-
idet P-40, 0.1% sodium dodecyl sulfate, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2 mM KH2PO4). Thirty micrograms of protein were resolved by SDS–PAGE and trans-
ferred to Immobilon-P membranes (Millipore Corp., Billerica, MA, USA). Membranes
were incubated with the primary antibodies anti-iNOS (1:1000; Cat No. sc-650, Santa
Cruz Biotechnology, Dallas, TX, USA), anti-SAA1/A2 (1:1000; Cat No. AF2948, R&D
Systems, USA) or anti-β-actin (1:50,000; Cat No. A3854, Sigma-Aldrich, Madrid, Spain).
Appropriate peroxidase-conjugated secondary antibodies (1:5000; Cat Nos. sc-2354 and
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sc-2357, Santa Cruz Biotechnology, USA) were used to detect proteins by enhanced chemi-
luminescence. Different band intensities were quantified using the Scion Image program
(RRID:SCR_008673). Immunoblot images correspond to a representative experiment.
2.13. Immunofluorescence
Mice were anesthetized i.p. with ketamine (100 mg/kg)/xylazine (10 mg/kg) and
through vascular perfusion brains were washed with saline solution to remove hemorrhagic
areas. Brains were extracted, embedded in OCT media, frozen at −80 ◦C, and sectioned in
15 µm thick slices using a cryostat (CM 1100, Leica Microsystems, Madrid, Spain). Brain
sections were fixed with 4% paraformaldehyde dissolved in PBS for 10 min and washed
three times with PBS every 5 min. After 2 h of blocking with 20% goat serum, tissue was
incubated overnight at 4 ◦C with the primary antibodies anti-APP (1:1000; Cat No. 36-6900,
ThermoFisher Scientific, Waltham, WA, USA) or anti-SAA1/A2 (1:100; Cat No. AF2948,
R&D Systems, USA) diluted in PBS with 0.3% Triton X-100. Then, incubation with fluo-
rescent secondary antibodies (1:500; Cat Nos. A-11057 and A-21206, Invitrogen, Carlsbad.
CA, USA) and nuclei staining with DAPI (1:1000; Cat No. D1306, ThermoFisher Scientific,
USA) was performed. Finally, the slides were covered with coverslips adding the mounting
medium Fluoromount-G (SouthernBiotech, Birmingham, AL, USA). Immunofluorescence
images were obtained using a Leica TCS-SP5 (Leica Microsystems, Madrid, Spain) confocal
microscope. In Figure 6, region (i) is referred to the nearest 50 µm and region (ii) between
50 and 100 µm. Images were processed with the program ImageJ 1.52e (ImageJ software,
National Institutes of Health, USA).
2.14. Statistics
Data are represented as median with interquartile range (Figures 1 and 2, and Figure S1
or means ± SD (Figures 3–7 and Figures S2 and S3). The analysis of normality was assessed
by D’Agostino–Pearson omnibus normality test for human and “in vivo” experiments.
Data distribution for “in vitro” studies was assumed to be normal. Statistical significance
between two groups was measured by 2-tailed unpaired t-test. For differences between
more than two groups with one independent factor, we used 1-way ANOVA with Tukey’s
multiple comparisons test when data followed normal distribution and the nonparametric
Kruskal–Wallis test with Dunn’s multiple comparisons test for data that not followed
normality. The experiments that had two different independent variables were analyzed by
2-way ANOVA with Sidak’s multiple comparisons test. Animals were randomly assigned
to the different groups before TBI induction and NSS evaluation was blinded. p < 0.05
was considered statistically significant. All statistical analysis and graphical representation
were performed using GraphPad Prism 6.0 software program (GraphPad Software Inc.,
San Diego, CA, USA. RRID:SCR_002798).
The discriminatory ability of SAA1/S100B levels at hospital admission regarding
dichotomized outcome and TBI detection was evaluated using the area under the receiver
operating characteristic curves. Sensitivity, specificity, and positive and negative predictive
values were calculated from contingency tables. Optimal cut points estimated from ROC
curves were selected prioritizing sensitivity (as “rule-out” test). Logistic regression analysis
was used to determine whether SAA1/S100B levels remained as an independent prognostic
factor for dichotomized outcome at 6 months when adjusted for other known factors
related to outcome. Data were analyzed with statistical package SPSS version 21.0 (IBM
Corporation, Armonk, NY, USA). p < 0.05 was considered statistically significant.
3. Results
3.1. Expression Profile of SAA1 and S100B and Their Correlation with Injury Severity
Table 1 shows the demographic characteristics of TBI patients included in the study.
First, we examined the levels of SAA1 protein at different times (24 h, 72 h, and 7 days)
after injury (Figure 1). We observed a significant increase in SAA1 serum levels after 24 h
(median = 280 µg/mL; IQR = 73.41–404.4), 72 h (median = 381.2 µg/mL; IQR = 161.9–642.9),
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and 7 days (median = 313.2 µg/mL; IQR = 117.8–500.4) post-TBI compared to control pa-
tients (Figure 1A). A peak and a plateau were reached at 72 h, which was maintained
significantly elevated at all time points after the injury. Changes in SAA1 levels in periph-
eral blood did not differ between male and female TBI patients, indicating no sex effects
(Figure S1). In the case of S100B, we only observed a significant increase in serum levels
at 24 h (median = 0.45 µg/L; IQR = 0.26–0.78), while values at 72 h (median = 0.25 µg/L;
IQR = 0.09–0.55) and 7 days (median = 0.12 µg/L; IQR = 0.06–0.29) were progressively
decreasing (Figure 1B).
Table 1. Demographic details of the patient cohort.
Controls 24 h 72 h 7 d
N (%) * 8 29 (85.3) 28 (82) 21 (61.7)
Sex,
male/female 4/4 22/7 21/7 16/5
Age, mean 44 ± 17.6 52.8 ± 18.3
Severity (GCS)
mild 15 15 10
moderate 4 3 4
severe 10 10 7
Outcome at 6
months (GOSE)
Favorable 13 13 8
Unfavorable 13 13 11
* Total number of patients was 34. It was not possible to obtain all the samples at the three time points from the
whole cohort. Some patients were lost in the GOSE as it was impossible to follow the patients 6 months after
the injury.
Next, we determined the correlation between SAA1 and S100B levels with clinical
parameters. First, we classified patients according to Glasgow Coma Scale (GCS) into
two groups: moderate–severe TBI (moderate, GCS 9–13; severe, GCS 3–8) and mild TBI
(GCS 14–15) (Table 1). Figure 1C shows no significant changes in SAA1 levels among the
mild-TBI group at any time tested. However, SAA1 levels in the moderate–severe group
were significantly higher at 72 h in comparison to 24 h, confirming that maximum SAA1
concentrations were reached 3 days after the injury. Furthermore, we found significant
differences between mild and moderate–severe groups at 72 h and 1 week after TBI.
Regarding S100B, only the values at 24 h were able to discriminate injury severity of patients
(Figure 1D). These data suggest SAA1 as an important mediator of the inflammatory
response in TBI, as it participates in the APR and remains altered in systemic circulation
during the first week post-injury.
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Wallis with Dunn’s multiple comparisons test. (C) Patients were classified in two groups of severity (mild and moder-
ate/severe) according to GCS. SAA1 serum levels correlated with severity at 72 h and 1 week post-trauma. * p < 0.05, ** p 
< 0.01, 2-way ANOVA with Sidak’s multiple comparisons test. (D) Patients were classified in two groups of severity (mild 
and moderate/severe) according to GCS. S100B levels correlated with severity at 24 h. * p < 0.05, 2-way ANOVA with 
Sidak’s multiple comparisons test. Data of all experiments are represented as median with interquartile range. 
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tween favorable and unfavorable outcome 6 months after the injury. We obtained a sen-
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(mild and moderate/severe) according to GCS. S100B levels correlated with severity at 24 h. * p < 0.05, 2-way ANOVA with
Sidak’s multiple comparisons test. Data of all experi ents are represented as median with interquartile range.
3.2. Correlation of SAA1 Alo e or i Combination with S100B with Neurological Outcome
6 Months after TBI
To determine the neurological outcome of TBI patients 6 months after TBI, we used the
Extended Glasgow Outcome Scale (GOSE), a global test to determine long-term functional
outcome of each patient after trauma [18]. Thus, we dichotomized patients into two
groups: unfavorable (GOSE 1–5) and favorable (GOSE 6–8) outcome. SAA1 remains
stable in patients with a favorable outcome, while plasma protein concentrations in the
unfavorable outcome group increased at 72 h after the injury (Figure 2A). This elevation
was significantly higher in the unfavorable compared with favorable outcom . To evaluate
whether serum SAA1 levels 72 h after TBI coul discriminate etween patients with
favorable and unfavorable outcomes, a ROC curve was calculated (Figure 2B). The area
under the curve (AUC) verified that SAA1 levels 72 h after TBI could discriminate between
the favorable and unfavorable outcomes of patients (AUC = 0.86, 95% CI = 0.72–1, p = 0.001).
With sensitivity set at 100%, SAA1 displayed a specificity of 46.2%. We also evaluated
SAA1 in the best scenario setting sensitivity in the 90 to 100% range. In this case, SAA1
reached 53.8% specificity, lowering its sensitivity to 92.3%. Moreover, we chose the cut-off
level of 381.2 µg/mL (blue dot in Figure 2B) as the best value to discriminate between
favo able and unfavorable outcome 6 months after the injury. We obtained a sensitivity of
84.62% and specificity of 69.2%. Finally, we calculated the positive and negative predictive
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values (PPV and NPV) at this cut-off level, and the obtained values were 73.3% and 80%,
respectively (Table 2).
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Figure 2. SAA1 levels 72 h after tra a predict TBI patients’ outcome at 6 months, S100B at 24 h, and a combination of both
biomarkers improves the ability of prediction. Functional outcome was assessed 6 months after trauma using the GOSE test
and patients were divided in two groups: favorable and unf vorable o tcome. (A) At 72 h, SAA1 levels were significantly
higher in the unfavorable outcome group. * p < 0.05, 2-way ANOVA with Sidak’s multiple comparisons test. (B) Receiver
operating curve (ROC) for SAA1 levels at 72 h after hospital admission to predict possible differences between “favorable”
(n = 13) and “unfavorable” (n = 13) outcome. Blue dots represent the value for sensitivity and specificity shown in Table 2.
(C) At 24 h, S100B in serum is increased in the unfavorable outcome group. ** p < 0.01, 2-way ANOVA with Sidak’s multiple
comparisons test. (D) Receiver operating curve (ROC) for S100B levels at 24 h after hospital admission to predict possible
differences between “favorable” (n = 13) and “unfavorable” (n = 13) outcome. (E) Receiver operating curve (ROC) that
combines SAA1 (72 h) and S100B (24 h) values to determine the discriminative capacity of the biomarker combination in
outcome 6 months after the injury (favorable, n = 13; unfavorable, n = 13). Data of 2A and 2C are represented as median
with interquartile range.
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Table 2. Clinical performance characteristics of SAA1 levels at 72 h as a predictor of outcome.
Sensitivity, specificity, PPV and NPV for the cut-off point selected are showed. PPV = Positive
Predictive Value; NPV = Negative Predictive Value.
Cut-Off (µg/mL) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
>381.2 84.62 69.2 73.3 80
Regarding S100B, Figure 2C shows that protein levels measured at 24 h were signif-
icantly higher in the unfavorable group. Moreover, the ROC curve demonstrated that
S100B levels measured at 24 h predicts patients’ outcome at 6 months (Figure 2D) and, as
in the case of SAA1, it could discriminate between favorable and unfavorable outcomes of
patients (AUC = 0.75, 95% CI = 0.565–0.935, p < 0.05). Finally, in order to try to enhance
prognosis capacity, we combined both biomarkers in a ROC curve (Figure 2E). As a result,
we obtained higher AUC values with the combination of both biomarkers than isolated
ones (AUC = 0.93, 95% CI = 0.8267–1, p < 0.001). To sum up, we found that SAA1 discrim-
inates patients according to the severity of TBI and its measurement 3 days post-injury
predicts the outcome of the patients 6 months later. Furthermore, the combination of SAA1
and S100B measurements improved the prognosis of outcome compared to each biomarker
analyzed independently.
3.3. Positive Correlation between SAA1 Serum Levels and TLR4 mRNA in White Blood Cells from
Human TBI Patients
Endogenous SAA1 signals via TLR2/4 in different immune cells [19–23]. On the other
hand, TLR2/4 expression is associated to outcome in stroke patients [24]. To examine
whether SAA1 is relevant for inflammation after TBI, we studied TLR4 expression on white
blood cells (WBC) of TBI patients 24 h, 72 h, and 7 days after TBI. As in the case of SAA1,
we observed an increase in TLR4 mRNA at 24 h (median = 10.51; IQR = 2.26–28.15), 72 h
(median = 11.24; IQR = 2.42–15.34), and 7 days (median = 9.74; IQR = 2.42–15.34) post-TBI
(Figure 3A). Significant differences were obtained at 24 h and 72 h after TBI. Next, we
examined the relationship between TLR4 expression and serum SAA1 levels. A positive
correlation was found at 72 h post-TBI (Pearson coefficient = 0.6395, p < 0.05) (Figure 3B).
Altogether, our data indicate that serum SAA1 levels, TLR4 expression, and the severity
and the outcome of patients could be mechanistically linked.
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Figure 3. TLR4 mRNA levels increase in circulating leucocytes during the first week after trauma
and determination at 72 h positively correlates with SAA1 serum levels. (A) Q-PCR determined that
TLR4 mRNA levels of cir ulating blood cells significantly i crease a 24 h (n = 13) and 72 h (n = 11) in
trauma patients compared to controls (n = 7). At 7 days (n = 10), there were no significant differences.
* p < 0.05, 1-way ANOVA with Dunnett’s multiple comparisons test. (B) A correlation analysis
(10 patients) between TLR4 mRNA of blood cells and SAA1 serum levels at 72 h was determined.
The correlation coefficient (r = 0.6395) detected positive correlation between the variables. In
the correlation analysis test, p < 0.05 was establish d to determine a true correlation. Data of all
experiments are represented as median with interquartile range.
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3.4. SAA1 Contributes to Inflammation in Glial Cultures via TLR4 Activation
Once a positive correlation between SAA1 serum levels and TLR4 mRNA with sig-
nificant predictive value for severity and patient outcome was established, we explored
the role of SAA1 in brain inflammation. For this purpose, we used primary mixed glial
cultures from mice treated with SAA1 recombinant protein at 1 µg/mL and 3 µg/mL
and determined the levels of the proinflammatory cytokine IL-1β (Figure 4A). At both
concentrations tested, we obtained a significant increase in IL-1β release levels, so we
selected the concentration of 1 µg/mL to perform further experiments. After 24 h of in-
cubation, we detected an increase in the proinflammatory cytokines TNF-α and IL-1β by
ELISA (Figure 4B), and an increase in the inducible nitric oxide synthase (iNOS) enzyme
by Western blot (Figure 4C). To further demonstrate that SAA1 exerts its inflammatory
response through TLR4 receptors [25,26], we co-treated glial cells with SAA1 1 µg/mL with
TAK242 (1 µM), a specific TLR4 antagonist, for 24 h. We obtained a significant reduction
in the release of TNF-α and IL-1β to the culture medium (Figure 4B), as well as in iNOS
protein levels in cell lysates (Figure 4C).
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in primary mixed glial cultures. (A) Glial cultures were treated with SAA1 (1 and 3 µg/mL) with or
without TAK242 (1 µM) during 24 h. ELISA revealed a significant increase of IL-1β release to culture
medium (n = 3). * p < 0.05, ** p < 0.01, 1-way ANOVA test with Tukey’s multiple comparisons test.
(B) ELISA analysi reveal d that TAK242 preve ed the increase of IL-1β (n = 4) and TNF-α (n = 5)
produced by SAA1. * p < 0.0 , ** p < 0.01, # p < 0.05, ## p < 0.01,1-way ANOVA test with Tukey’s
multiple comparisons test. (C) Representative immunoblot and quantification of iNOS expression
in cultures treated with SAA1 with or without TAK242 (n = 6). * p < 0.05, 1-way ANOVA test with
Tukey’s multiple comparisons test. Data of all experiments are represented as mean ± SD.
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Once proven that SAA1 can trigger an inflammatory response in glial cells, we exam-
ined whether proinflammatory stimuli such as IL-1β and TNF-α (10 ng/mL) enhanced
SAA1 synthesis and release. SAA1 levels in glial cultures were significantly increased
by IL-1β and TNF-α (Figure 5A). We then treated cultured glia with LPS (1 µg/mL), a
well-known TLR4 agonist, to trigger inflammatory cascade. Twenty-four hours of LPS
treatment induced an increase in the levels of SAA1 that was reduced by ~50% in the pres-
ence of TAK242 (Figure 5B). These results indicate that SAA1 generates a positive feedback
loop in glial cells. First, SAA1 and other DAMPs promote the release of inflammatory
cytokines (IL-1β and TNF-α) that in turn stimulate SAA1 production, which potentiate the
inflammatory response. TLR4 antagonism decreases SAA1 release, thereby reducing the
effects of this loop.
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lotting of cerebral tissue revealed that SAA1 is not present in brains of non-injured ani-
mals (Figure 6C). The levels of SAA1 increased in the ipsilateral hemisphere of TBI mice, 
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3.5. Post-TBI Treatment wit R4 Antagonist TAK242 Reduces SAA1 Levels
Having verified that T 242 reduced the downstream effects of SAA1 in vitro, we
tested if the compound had beneficial effects in vivo. C57BL/6J mice subjected to CHI
were treated for 1 h post-TBI with TAK242 (3 mg/kg, i.p.). First, we assessed SAA1
levels in blood serum and brain parenchyma 24 h after the injury. We observed that
TLR4 antagonism significantly reduced SAA1 levels compared to non-treated animals in
both serum and brain (Figure 6A,B). No differences were detected neither in serum nor
cerebral cortex 1 week after TBI between vehicle and TBI groups (Figure S2). To confirm
th se findings, we performed Wester blot and immunofluo scence analysis against SAA1.
Immunoblotting of cere ral tissue revealed that SAA1 is not present in brains of non-injured
animals (Figure 6C). The levels of SAA1 increased in the ipsilateral hemisphere of TBI mice,
while they were undetectable in the contralateral hemisphere. Moreover, treatment of TBI
animals with TAK242 diminished SAA1 accumulation in brain parenchyma of the injured
hemisphere (Figure 6C). Next, we performed immunofluorescence of SAA1 in brain slices
from TBI animals (Figure S3A shows the analyzed regions). SAA1 labeling was detected
24 h post-injury in the damaged area, as well as in the penumbra area of the ipsilateral
hemisphere (Figure 6D). TAK242 treatment reduces SAA1 staining in the damaged region
(Figure 6D). Quantification of the SAA1-positive area confirmed that TAK242 almost
compl tely red c d brain levels of the protein (Figure 6E). No SAA1 sta ing was detected
in the contralateral hemisphere at 24 h or in the ipsilateral and contralateral areas 7 days
after TBI (Figure S3B–D). These findings suggest that SAA1 is an important mediator of
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the acute inflammatory response, as SAA1 levels arise in systemic circulation and, most
important, in brain parenchyma 24 h after TBI in mice.
Amyloid precursor protein (APP) is used as an indicative of axonal injury as it accu-
mulates as a result of axonal transport system disruption [27]. Therefore, to confirm the
presence of axonal injury in our model, we used immunofluorescence of APP in brain slices
from TBI animals. We found APP presence at both 24 h and 7 d.a.i in the ipsilateral cortex
(Figure 6G), but not in contralateral cortex (Figure S3B). We also evaluated the possibility
that TAK242 could prevent damage spreading along the injury site. APP particles were
significantly lowered 24 h and 7 d.a.i by the treatment with TAK242 (Figure 6F,G), which
means that TLR4 antagonism reduces the extent of diffuse axonal injury both at 24 h and
7 days after TBI.
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Figure 6. TLR4 antagonism decreased serum and brain SAA1 levels 1 day after TBI. (A) TAK242 (3 mg/kg) reduced serum 
SAA1 protein levels. Mice were treated 1 h after CHI (sham, n = 8; vehicle, n = 10; TAK, n = 8). * p < 0.05 and *** p < 0.001, 
1-way ANOVA with Tukey’s multiple comparisons test. (B) Treatment reduced cerebral accumulation of SAA1 at one day 
post-injury (sham, n = 4; vehicle, n = 11; TAK, n = 9). * p < 0.05, 1-way ANOVA with Tukey’s multiple comparisons test. (C) 
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SAA1 protein levels. Mice were treated 1 h after CHI (sham, n = 8; vehicle, n = 10; TAK, n = 8). * p < 0.05 and *** p < 0.001, 
1-way ANOVA with Tukey’s multiple comparisons test. (B) Treatment reduced cerebral accumulation of SAA1 at one day 
post-injury (sham, n = 4; vehicle, n = 11; TAK, n = 9). * p < 0.05, 1-way ANOVA with Tukey’s multiple comparisons test. (C) 
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Figure 6. TLR4 antagonism decreased serum and brain SAA1 levels 1 day after TBI. (A) TAK242 (3 mg/kg) reduced serum
SAA1 protein levels. Mice were treated 1 h after CHI (sham, n = 8; vehicle, n = 10; TAK, n = 8). * p < 0.05 and *** p < 0.001,
1-way ANOVA with Tukey’s multiple comparisons test. (B) Treatment reduced cerebral accumulation of SAA1 at one day
post-injury (sham, n = 4; vehicle, n = 11; T K, n = 9). * p < 0.05, 1-way ANOVA with Tukey’s multiple comparisons test.
(C) Brain lysates of mice treated with or without TAK242 were immunoblotted with SAA1 antibody and protein expression
was quantified (sham, n = 4; vehicle ipsi and contra, n = 4; TAK242 ipsi and contra, n = 4). * p < 0.05, ** p < 0.01, 1-way
ANOVA with Tukey’s multiple comparisons test. (D) SAA1 immunostainings and (E) quantification of SAA1 positive
area of (i) and (ii) brain regions of mice subjected to TBI at the indicated time points, treated or not with TAK242 (vehicle
ipsi and contra, n = 3; TAK242 ipsi and contra, n = 3). ** p < 0.01, 2-way ANOVA with Sidak’s multiple comparisons test.
(F) Quantification of APP particles of (i) and (ii) regions and (G) APP immunostainings of brains of mice subjected to TBI
at the indicated time points, treated or not with TAK242 (vehicle ipsi and contra, 24 h and 7 d, n = 4; TAK242 ipsi and
contra, 24 h and 7 d, n = 4). *** p < 0.01, # p < 0.05, 2-way ANOVA with Sidak’s multiple comparisons test. Photos show
the damaged hemisphere in an area immediately surrounding the injury site ((i) the nearest 50 µm) and in a deeper area
((ii) between 50 and 100 µm). Images are representative of each group. Scale bars: 5 µm. White arrows indicate the limit
of the cortical damaged area. Data of all experiments are represented as mean ± SD. Ipsi, ipsilateral hemisphere; contra,
contralateral hemisphere.
3.6. Treatment with TAK242 Improves Neurobehavioral Outcome and Prevents Blood-Brain
Barrier Disruption
As TLR4 is one of the main contributors to inflammation in brain [9,10,28], we explored
the possible effects of its inhibition in the functional outcome of animals subjected to CHI.
We used the neurological severity score (NSS) test, which evaluates neurologic, motor, and
behavioral skills in mice after TBI [17]. A score of 10 points represents a total neurological
impairment, whereas 0 points means a normal function. One hour after TBI, we detected that
animals obtained a NSS between 6 and 8 (sham animals had a score of 0 or 1, data not shown).
Following the 1-h test, animals were treated with TAK242 (3 mg/kg) and NSS was assessed
again 24 h after the injury. In this case, we found that TAK242-treated animals significantly
improved neurobehavioral skills compared to saline vehicle animals (Figure 7A). Next, we
examined if the NSS improvement was related to a reduction in BBB breakdown. For that,
we measured the extravasation of Evans Blue dye into cerebral tissue at different time points
after CHI. First, we analyzed Evans Blue leakage in non-injured mice, and we did not find
stained areas (data not shown). One hour post-TBI, Evans Blue dye only penetrated in the
cortex surrounding the injury, while the following day, vehicle-treated mice had almost the
whole ipsilateral hemisphere stained (Figure 7B). TAK242 treatment 1 h after TBI significantly
reduced Evans Blue leakage in brain parenchyma compared to those vehicle-treated group
(Figure 7B). Finally, we assessed the BBB permeability 7 d.a.i. and found a spontaneous
recovery of vasculature stability in our model of TBI (Figure 7B). This evidence reveals that
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TLR4 plays an important role in BBB disruption and its blockade promotes beneficial effects
on neurological parameters after TBI in mice.




Figure 7. TAK242 improves NSS score and Blood–Brain Barrier (BBB) impairment produced by trauma. (A) Immediately 
following the 1-h NSS test, mice were treated with vehicle solution (0.9% NaCl) or TAK242 (3 mg/kg). NSS was repeated 
in the same mice 1 d.a.i (vehicle, n = 10; TAK, n = 8). ** p < 0.01, 2-way ANOVA with Sidak’s multiple comparisons test. (B) 
Mice were injected intraperitoneally with Evans Blue dye (2%) after the 1-h NSS test in vehicle and TAK242 groups and 
were sacrificed 24 h later. For 1 h group, it was injected immediately after TBI. For 7 d group, Evans Blue was injected the 
day before sacrifice. Brains were cut in 2 mm slices to analyze the stained brain surface (1 h, n = 5; vehicle, n = 7; TAK242, 
n = 7; 7 d, n = 6). * p < 0.05, ** p < 0.01, *** p < 0.001, 1-way ANOVA with Tukey’s multiple comparisons test. Representative 
photographs of the four 2-mm slices obtained in each brain are shown above the graph. 
4. Discussion 
Herein, we identified a direct link between SAA1 and TLR4 in traumatic brain injury, 
which positively correlated with injury severity and 6-month outcome of patients, as well 
as with BBB breakdown and worse outcome in animals. The use of plasma biomarkers is 
a priority in current personalized medicine. In the context of TBI, biomarkers have the 
potential to be used as diagnostic markers of injury severity, markers of response to treat-
ment (monitoring biomarkers), or even as predictors of outcomes after trauma (predictive 
biomarkers). As most biomarker validations are conducted 24 h after brain trauma [29–
31], the time course of biomarkers has been poorly studied. However, some groups have 
recently started to determine the kinetics of TBI biomarkers at longer times to predict out-
come and other clinical parameters [32]. We provide here an example of a time course 
evaluation of a potential biomarker combination for prediction and, possibly, for patient 
follow-up and monitoring drug responses. The predictive value of serum SAA1 is better 
Figure 7. TAK242 improves NSS score and Blood–Brain Barrier (BBB) impairment produced by
trauma. (A) Immediately following the 1-h NSS test, mice were treated with vehicle solution
(0.9% NaCl) or TAK242 (3 mg/kg). NSS was repeated in the same mice 1 d.a.i (vehicle, n = 10; TAK,
n = 8). ** p < 0.01, 2-way ANOVA with Sidak’s multiple comparisons test. (B) Mice were injected
intraperitoneally with Evans Blue dye (2%) after the 1-h NSS test in vehicle and TAK242 groups and
were sacrificed 24 h later. For 1 h group, it was injected immediately after TBI. For 7 d group, Evans
Blue was injected the day before s crifice. Br ins were cut in 2 mm slices to analyze the stained brain
surface (1 h, n = 5; vehicle, n = 7; TAK242, n = 7; 7 d, n = 6). * p < 0.05, ** p < 0.01, *** p < 0.001, 1-way
ANOVA with Tukey’s multiple comparisons test. Representative photographs of the four 2-mm slices
obtained in each brain are shown above the graph.
4. Discussion
Herein, we identified a direct link between SAA1 and TLR4 in traumatic brain injury,
which positively correlated with injury severity and 6-month outcome of patients, as well
as with BBB breakdown and worse outcome in animals. The use of plasma biomarkers
is a priority in current personalized medicine. In the context of TBI, biomarkers have
the potential to be used as diagnostic markers of injury severity, markers of response
to treatment (monitoring biomarkers), or even as predictors of outcomes after trauma
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(predictive biomarkers). As most biomarker validations are conducted 24 h after brain
trauma [29–31], the time course of biomarkers has been poorly studied. However, some
groups have recently started to determine the kinetics of TBI biomarkers at longer times to
predict outcome and other clinical parameters [32]. We provide here an example of a time
course evaluation of a potential biomarker combination for prediction and, possibly, for
patient follow-up and monitoring drug responses. The predictive value of serum SAA1 is
better at 72 h than 24 h or 7 days after brain trauma. Moreover, it improves the predictive
value obtained for S100B at 24 h after TBI. However, the most important point is that the
combination of both biomarkers (measured at different times post-TBI, 24 h for S100B
and 72 h for SAA1) has the best predictive value of all combinations tested. On the other
hand, we have observed a possible mechanistic link between inflammation and outcome of
TBI patients, as values of serum SAA1 positively correlates with TLR4 mRNA obtained
from WBC from patients at the same time point (72 h). Recently, it has been shown that
TLR4 expression in WBC correlates with poor outcome in ischemic stroke patients [24,33].
Therefore, as in stroke, an important inflammatory response is triggered after TBI that
could be dramatically increased by the important rise of SAA1 serum levels.
Clinically, it is important to understand the pathophysiological alteration of SAA1
in TBI patients. Our data suggest that SAA1 remained elevated up to 1 week post-TBI.
Considering the results obtained in in vitro and in vivo models, it is plausible that SAA1
activates the TLR4 of inflammatory cells inducing the release of inflammatory mediators
such as interleukins (IL-1β, TNF-α, among others). These inflammatory mediators, in
turn, increase SAA1 through activation of their respective inflammatory receptors. We
propose that this cascade of events produces a positive inflammatory loop that serves to
perpetuate the inflammatory response. Thus, blocking one step of this inflammatory loop
may represent a suitable therapeutically option in TBI patients. This is the case of the
TLR4 blocker resatorvid (TAK242), which improves the outcome of animals, avoids BBB
breakdown, and reduces the brain levels of SAA1.
The role of inflammation in the progression of different diseases, like neurodegener-
ative diseases, is well known [34–36]. We have shown that recombinant SAA1 activates
TLR4 inflammatory receptor in vitro. Our data are in line with the literature, describing
the participation of SAA1 in the inflammatory response of TLR2/4 activation in periodon-
titis [23], myotube atrophy [37], or sepsis [20], among others. Our results may help to shed
light about the relationship between SAA1-TLR4 axis and BBB breakdown. Thus, TLR4
blockade could improve BBB breakdown, and thereby reduce to control levels the presence
of SAA1 in the brain. It has been recently described that overexpressed liver-derived SAA1
protein in mice accumulates in the brain crossing the BBB, triggering a depressive-like
behavior of mice [38]. Moreover, in double transgenic APP/SAA1 mice, SAA1 exacerbated
amyloid aggregation, glial activation, causing greater memory decline in APP/SAA1 com-
pared to single transgenic APP mice [39]. Other studies in humans showed that SAA1
was detected in senile plaques in Alzheimer’s disease tissue, predominantly localized to
neuritic plaques [40]. All together, these studies point to brain SAA1 levels as a trigger
of amyloid aggregation or co-aggregation with SAA1. This pathological process may be
taking place in chronic traumatic encephalopathy (CTE) of TBI patients in collision sports,
which may lead to worsen the cognitive function of TBI patients.
Of clinical importance, our data suggest a mechanistic biomarker-guided stratification,
using SAA1 protein and TLR4 mRNA. Therefore, we would modulate drug treatment
to those patients with an unfavorable outcome, which have a high likelihood to worsen
from this inflammatory loop, and thus reduce the number of patients with poor prognosis.
In addition, focusing on biomarkers that share the SAA1-TLR4 inflammatory axis will
ensure that a personalized and not standard dose can be applied and will further reduce
possible dropouts. Finally, our findings provide a clear rationale for further development of
a pharmacological SAA1/TLR4 axis inhibition as a first-in-class pharmacological strategy
to stop unfavorable outcome in TBI patients.
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Víctor Farré-Alins, Alejandra Palomino-Antolín, Paloma Narros-Fernández, Juliana M.
Rosa, José María Roda-Frade, Cristina S. Carabias, Santiago Yus-Teruel, Luis Gandía, Alfonso
Lagares, Borja J. Hernández-García and Javier Egea. Método para determinar la evolución del
daño cerebral agudo y composición farmaceútica para su tratamiento. EP202031194.
Supplementary Materials: Supplementary materials can be found at https://www.mdpi.com/
article/10.3390/biomedicines9060599/s1. Figure S1. Gender did not affect to SAA1 concentrations
after trauma. There were no statistical differences between men and women in SAA1 levels at 24 h,
72 h and 1 week post-injury. 2-way ANOVA with Sidak’s multiple comparisons test. Data are
represented as median with interquartile range. Figure S2. SAA1 levels increased in serum and brain
parenchyma 24 hours after traumatic brain injury and returned to basal levels 7 days post-injury.
(A) ELISA of SAA1 determined an early increase in protein levels that diminished 7 d.a.i. (sham,
n = 8; 1 d, n = 10; 7 d, n = 8). *** p < 0.001, 1-way ANOVA with Tukey’s multiple comparisons test.
(B) TBI lead to SAA1 accumulation in the injured hemisphere 1 d.a.i., which decreases 1 week later
(sham ipsilateral and contralateral, n = 4; 1d ipsilateral and contralateral, n = 11; 7d ipsilateral and
contralateral, n = 5). * p < 0.05, ** p < 0.01, 2-way ANOVA with Sidak’s multiple comparisons test.
Data of all experiments are represented as mean ± SD. Figure S3. SAA1 returns to basal levels and
APP remains expressed 7 days after injury in the ipsilateral cortex. (A) Illustration showing the areas
where immunofluorescence images were taken in the ipsilateral hemisphere. (B) Coronal sections of
brains of mice subjected to TBI were immunostained for SAA1 and APP at 24 h or 7 days after trauma.
DAPI was used to stain nucleus. Microscopy pictures were taken at the ipsilateral hemisphere,
in an area immediately surrounding the injury site (i, the nearest 50 µm) and in the adjacent area
(ii, between 50 and 100 µm). (C) Illustration showing the areas where immunofluorescence images
were taken in the contralateral hemisphere. (D) Immunofluorescence images for SAA1 and APP in
the contralateral hemisphere of injured mice brains 24 h or 7 days post-TBI. Scale bars: 5 µm. White
arrows indicate the limit of the cortical damaged area.
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